Annovis Bio (ANVS) Competitors $2.73 +0.01 (+0.37%) Closing price 08/15/2025 03:58 PM EasternExtended Trading$2.71 -0.02 (-0.70%) As of 08/15/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, TRDA, OGI, IPHA, GNFT, CTMX, EPRX, ENGN, PBYI, and EDITShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Entrada Therapeutics (TRDA), Organigram Global (OGI), Innate Pharma (IPHA), GENFIT (GNFT), CytomX Therapeutics (CTMX), Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Puma Biotechnology (PBYI), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Entrada Therapeutics Organigram Global Innate Pharma GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals enGene Puma Biotechnology Editas Medicine Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk. Do analysts prefer ANVS or ALXO? Annovis Bio currently has a consensus price target of $18.00, suggesting a potential upside of 559.34%. ALX Oncology has a consensus price target of $3.30, suggesting a potential upside of 412.18%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is ANVS or ALXO more profitable? ALX Oncology's return on equity of -115.67% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -206.01% -158.26% ALX Oncology N/A -115.67%-84.82% Which has higher valuation and earnings, ANVS or ALXO? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.04-1.34ALX OncologyN/AN/A-$134.85M-$2.20-0.29 Does the media favor ANVS or ALXO? In the previous week, Annovis Bio and Annovis Bio both had 7 articles in the media. Annovis Bio's average media sentiment score of 0.87 beat ALX Oncology's score of -0.35 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility and risk, ANVS or ALXO? Annovis Bio has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ANVS or ALXO? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryALX Oncology beats Annovis Bio on 7 of the 12 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$53M$3.10B$5.68B$20.90BDividend YieldN/A2.23%3.79%3.58%P/E Ratio-1.3420.8931.0828.00Price / SalesN/A366.96467.0155.80Price / CashN/A42.3037.4023.77Price / Book2.908.659.095.26Net Income-$24.59M-$54.65M$3.26B$994.11M7 Day Performance6.68%6.56%7.36%1.80%1 Month Performance-2.05%7.53%5.47%1.74%1 Year Performance-67.92%13.69%30.61%13.36% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.6679 of 5 stars$2.73+0.4%$18.00+559.3%-69.2%$53MN/A-1.343News CoverageEarnings ReportALXOALX Oncology2.9095 of 5 stars$0.61-9.2%$3.30+437.0%-75.7%$36.14MN/A-0.2540Earnings ReportGap DownTRDAEntrada Therapeutics2.5864 of 5 stars$5.02-3.3%$25.67+411.3%-67.6%$197.41M$210.78M-2.82110OGIOrganigram Global1.0385 of 5 stars$1.64+13.5%N/A-28.1%$193.67M$117.47M16.40860News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeIPHAInnate Pharma2.2421 of 5 stars$2.06-1.9%$11.00+434.0%-5.1%$193.59M$21.77M0.00220Short Interest ↑GNFTGENFIT2.1663 of 5 stars$3.73-1.8%$13.00+248.5%-7.2%$190.01M$76.77M0.00120High Trading VolumeCTMXCytomX Therapeutics3.9498 of 5 stars$2.31-1.7%$5.75+148.9%+60.5%$189.46M$138.10M4.13170Analyst RevisionEPRXEupraxia Pharmaceuticals1.9756 of 5 stars$5.32+1.1%$11.00+106.8%+104.6%$189.15MN/A-7.0029News CoveragePositive NewsEarnings ReportAnalyst RevisionENGNenGene3.338 of 5 stars$3.69+0.3%$23.29+531.0%-37.6%$188.07MN/A-2.2431News CoverageShort Interest ↓PBYIPuma Biotechnology3.7047 of 5 stars$4.85+31.4%$7.00+44.3%+116.2%$185.87M$230.50M4.95200High Trading VolumeEDITEditas Medicine4.2778 of 5 stars$2.20-0.5%$4.70+113.6%-24.3%$185.01M$32.31M-0.72230News CoverageEarnings ReportAnalyst ForecastGap Up Related Companies and Tools Related Companies ALX Oncology Competitors Entrada Therapeutics Competitors Organigram Global Competitors Innate Pharma Competitors GENFIT Competitors CytomX Therapeutics Competitors Eupraxia Pharmaceuticals Competitors enGene Competitors Puma Biotechnology Competitors Editas Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access